News archive
News Archive Navigation
icon
News Archive Navigation Language
Showing 673 results
November 2023
-
Media ReleaseNovartis Issues Voluntary US Nationwide Recall of Two Lots of Sandimmune® Oral Solution (cyclosporine oral solution, USP), 100 mg/mL due to CrystallizationCompany Contact: Novartis Pharmaceuticals Corporation 1-888-669-6682 Novartis Media Relations E-mail: [email protected] North America Julie Masow …
-
Remembering men’s health this National Veterans and Military Families Month
Novartis honors veterans and military families this month, highlighting their support and raising awareness on men’s health, especially prostate cancer’s impact on veterans.
October 2023
-
Media ReleaseFDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decadeFDA approval based on robust Phase III data in which Cosentyx® (secukinumab) showed rapid relief from symptoms of hidradenitis suppurativa (HS) as early as Week 21 As the only IL-17A…
-
Media ReleaseNovartis confirms unconstrained supply for Pluvicto® and continues to significantly expand the number of treatment centersUS FDA has classified drug shortage status as resolved1Novartis capacity to produce Pluvicto will continue to grow with anticipated expansions to the manufacturing network in the US and globally…
-
Media ReleaseNovartis Pluvicto® shows clinically meaningful and highly statistically significant rPFS benefit in patients with PSMA-positive metastatic castration-resistant prostate cancer in the pre-taxane settingPhase III PSMAfore trial with Pluvicto® met its primary endpoint of radiographic progression-free survival (rPFS) with a HR of 0.411; Pluvicto more than doubled median rPFS to 12.0 months per…
-
Media ReleaseFDA approves Novartis Cosentyx® as first intravenous (IV) formulation interleukin-17A antagonist for rheumatic diseasesFirst new intravenous (IV) treatment option in six years for adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA)1-6 Cosentyx…
September 2023
-
Know the Facts and Be an Advocate This Prostate Cancer Awareness Month
Novartis is sharing information and resources to empower people affected by prostate cancer during Prostate Cancer Awareness Month
-
Media ReleaseNovartis Issues Voluntary Nationwide Recall of One Lot of Sandimmune® Oral Solution (cyclosporine oral solution, USP), 100 mg/mL due to CrystallizationCompany Contact: Novartis Pharmaceuticals Corporation 1-888-669-6682 EAST HANOVER, N.J., Sept. 11, 2023 -- Novartis is conducting a voluntary nationwide recall at the consumer level of one lot…
July 2023
-
Media ReleaseNovartis strengthens commitment to Beacon of Hope initiative, engages new collaborators to support clinical trial diversity, break down economic and education barriersAdvarra, Virb and BeeKeeperAI sign on to Beacon of Hope to provide suite of digital tools to facilitate clinical trials and research on healthcare inequities at Historically Black Medical School…
-
Media ReleaseUS FDA approves expanded indication for Novartis Leqvio® (inclisiran) to include treatment of adults with high LDL-C and who are at increased risk of heart diseaseExpanded indication now enables broader use of Leqvio for LDL-C reduction in patients with primary hyperlipidemia (high LDL-C) 1 Leqvio can now be used earlier in LDL-C treatment as an adjunct to…
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 57
- › Next page